Natixis’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $33.9M | Sell |
540,063
-13,948
| -3% | -$1.12M | 0.12% | 118 |
|
|
2025
Q4 | $52.8M | Buy |
554,011
+8,343
| +2% | +$818K | 0.19% | 74 |
|
|
2025
Q3 | $53.3M | Buy |
545,668
+55,582
| +11% | +$5.76M | 0.25% | 60 |
|
|
2025
Q2 | $52.6M | Sell |
490,086
-62,405
| -11% | -$6.31M | 0.23% | 61 |
|
|
2025
Q1 | $55.4M | Buy |
552,491
+23,477
| +4% | +$2.36M | 0.3% | 50 |
|
|
2024
Q4 | $47.3M | Sell |
529,014
-106,994
| -17% | -$9.42M | 0.29% | 63 |
|
|
2024
Q3 | $53.3M | Buy |
636,008
+158,978
| +33% | +$12.5M | 0.3% | 62 |
|
|
2024
Q2 | $36.7M | Sell |
477,030
-11,122
| -2% | -$814K | 0.21% | 81 |
|
|
2024
Q1 | $33.4M | Sell |
488,152
-211,580
| -30% | -$13.6M | 0.17% | 103 |
|
|
2023
Q4 | $40.5M | Buy |
699,732
+627,703
| +871% | +$33.5M | 0.29% | 81 |
|
|
2023
Q3 | $3.8M | Sell |
72,029
-16,624
| -19% | -$872K | 0.03% | 316 |
|
|
2023
Q2 | $4.8M | Sell |
88,653
-316,990
| -78% | -$16.6M | 0.04% | 296 |
|
|
2023
Q1 | $20.3M | Buy |
405,643
+212,591
| +110% | +$10M | 0.18% | 116 |
|
|
2022
Q4 | $8.93M | Buy |
193,052
+70,415
| +57% | +$3.05M | 0.05% | 284 |
|
|
2022
Q3 | $4.78M | Sell |
122,637
-27,649
| -18% | -$1.11M | 0.02% | 421 |
|
|
2022
Q2 | $5.61M | Sell |
150,286
-451,411
| -75% | -$18.4M | 0.02% | 420 |
|
|
2022
Q1 | $26.6M | Sell |
601,697
-1,157,739
| -66% | -$50.2M | 0.09% | 210 |
|
|
2021
Q4 | $74.7M | Buy |
1,759,436
+1,000,868
| +132% | +$42.1M | 0.26% | 63 |
|
|
2021
Q3 | $32.9M | Buy |
758,568
+336,101
| +80% | +$14.9M | 0.11% | 166 |
|
|
2021
Q2 | $18.1M | Buy |
422,467
+305,432
| +261% | +$12.8M | 0.08% | 204 |
|
|
2021
Q1 | $4.52M | Sell |
117,035
-161,086
| -58% | -$6.1M | 0.01% | 531 |
|
|
2020
Q4 | $10M | Buy |
278,121
+78,850
| +40% | +$2.84M | 0.04% | 389 |
|
|
2020
Q3 | $7.61M | Buy |
199,271
+162,633
| +444% | +$6.27M | 0.06% | 215 |
|
|
2020
Q2 | $1.29M | Sell |
36,638
-8,651
| -19% | -$312K | 0.01% | 492 |
|
|
2020
Q1 | $1.48M | Sell |
45,289
-338,044
| -88% | -$13.2M | 0.01% | 429 |
|
|
2019
Q4 | $17.2M | Sell |
383,333
-371,789
| -49% | -$15.6M | 0.11% | 204 |
|
|
2019
Q3 | $30.7M | Buy |
+755,122
| New | +$32M | 0.2% | 113 |
|
|
2019
Q2 | – | Sell |
-228,976
| Closed | -$8.68M | – | 771 |
|
|
2019
Q1 | $8.68M | Buy |
228,976
+52,291
| +30% | +$2M | 0.05% | 297 |
|
|
2018
Q4 | $6.24M | Buy |
176,685
+70,551
| +66% | +$2.56M | 0.05% | 289 |
|
|
2018
Q3 | $4.09M | Buy |
106,134
+50,279
| +90% | +$1.76M | 0.02% | 400 |
|
|
2018
Q2 | $1.83M | Sell |
55,855
-139,760
| -71% | -$4.22M | 0.01% | 536 |
|
|
2018
Q1 | $5.34M | Sell |
195,615
-827,200
| -81% | -$22.5M | 0.03% | 352 |
|
|
2017
Q4 | $25.4M | Buy |
1,022,815
+915,494
| +853% | +$25.3M | 0.2% | 125 |
|
|
2017
Q3 | $3.13M | Sell |
107,321
-21,569
| -17% | -$596K | 0.03% | 339 |
|
|
2017
Q2 | $3.57M | Buy |
128,890
+46,412
| +56% | +$1.23M | 0.04% | 269 |
|
|
2017
Q1 | $2.05M | Sell |
82,478
-20,197
| -20% | -$491K | 0.03% | 306 |
|
|
2016
Q4 | $2.22M | Buy |
+102,675
| New | +$2.24M | 0.02% | 337 |
|
|
2015
Q2 | – | Sell |
-308,445
| Closed | -$5.47M | – | 375 |
|
|
2015
Q1 | $5.47M | Buy |
308,445
+13,606
| +5% | +$215K | 0.08% | 122 |
|
|
2014
Q4 | $3.91M | Hold |
294,839
| – | – | 0.05% | 139 |
|
|
2014
Q3 | $3.48M | Sell |
294,839
-1,165,000
| -80% | -$14.7M | 0.05% | 174 |
|
|
2014
Q2 | $18.6M | Sell |
1,459,839
-1,135,506
| -44% | -$14.8M | 0.22% | 101 |
|
|
2014
Q1 | $35.1M | Sell |
2,595,345
-23,077
| -0.9% | -$303K | 0.46% | 59 |
|
|
2013
Q4 | $31.5M | Sell |
2,618,422
-1,170,178
| -31% | -$13.8M | 0.27% | 81 |
|
|
2013
Q3 | $44.5M | Buy |
3,788,600
+3,733,500
| +6,776% | +$40.4M | 0.48% | 55 |
|
|
2013
Q2 | $511K | Buy |
+55,100
| New | +$467K | 0.01% | 323 |
|
Other funds holding BSX
VCM
VPM
Natixis's BSX Position: Q1 2026 in Review
Natixis reduced its Boston Scientific (BSX) stake by 2.5% in Q1 2026, selling an estimated $1.12M and leaving 540,063 shares worth $33.9M. The position accounts for 0.12% of the portfolio, ranked #118.
Natixis first reported a position in BSX in Q2 2013 and has held it in 45 quarters since. The position peaked at $74.7M in Q4 2021. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.
- Natixis held 540,063 shares of Boston Scientific worth $33.9M as of Q1 2026.
- Natixis sold 13,948 Boston Scientific shares in Q1 2026, an estimated $1.12M.
- Boston Scientific made up 0.12% of Natixis's portfolio in Q1 2026, its #118 holding.
- Natixis first reported a position in Boston Scientific in Q2 2013 and has held it in 45 quarters since.
- Natixis's Boston Scientific position peaked at $74.7M in Q4 2021.
- 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.
Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.